The Indian Pharmaceutical Industry today is in the front rank of India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharmacy Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.
Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharmacy Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control.
[...] The Indian Government's decision to allow 100 percent foreign direct investment into the drugs and pharmaceutical industry is expected to aid the growth of contract research in the country. Technology transfer to 100 percent Indian subsidiaries of MNCs is expected only in 2005. Indian pharmaceutical interests in making a mark on the global scene got a boost when Dr. Reddy's licensed two of its anti-diabetic molecules to Novo Nordisk and when Ranbaxy licensed its Novel Drug Delivery System (NDDS) of ciprofloxacin to Bayer. [...]
[...] Indian companies, in an effort to consolidate their position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R&D efforts and improve distribution to penetrate markets. Research and development has always taken the back seat amongst Indian pharmaceutical companies. In order to stay competitive in the future, Indian companies will have to refocus and invest heavily in R&D. The Indian pharmaceutical industry also needs to take advantage of the recent advances in biotechnology and information technology. [...]
[...] Thus, when we talk of research methodology we only talk of the research methods but also consider the logic behind the methods we use in the research methods but also consider the logic behind the methods we use in the context of our research methods study and explain why we are using a particular method or techniques and why we are not using other so that research results are capable of being evaluated either by the researcher himself or by other. [...]
[...] The data is collected in such a manner that the ambiguous nature of cause and effect relationship in the phenomenon in reduced to maximum extent. These designs are able to reduce the basis in the data collecting process, minimize the expenditure and increase the accuracy in prediction. These designs are guided by initial hypotheses and are developed to determine the frequency with which something occurs or how two variables very together. Method Of Data Collection Data collection methods are generally two types: Primary data Secondary data Primary Data : The primary data are those which are collection afresh and for the first and thus happen to be original in character. [...]
[...] MAJOR PLAYER At Wockhardt, we are not only alert to the immense potential of 'future', but have already let it take shape in our dreams, in our plans and in our activities. GAINING FUTURE IN DOMESTIC FORMULATION In the domestic markets we have maintained our number one position for brands Proxyvon, Spasmo-Proxyvon, Wokadine, Decdan, Tryptomer , Biovac-B etc. Our new generation fluoroquinolone SPARX has now gained the number one spot. We are consolidating our leadership position in fluid therapy segment and expanding our activities in cardiac specialties, medical nutrition and bio-pharmaceuticals. [...]
Online readingwith our online reader
Content validatedby our reading committee